整合质量指标的FMEA用于HPV基因分型检测全过程风险评估
本研究将失效模式与效应分析(FMEA)与质量指标(QI)整合,构建HPV基因分型检测的全过程前瞻性风险评估模型,以符合ISO 15189:2022并提升诊断准确性。多学科团队在分析前、分析中和分析后阶段实施FMEA,并通过分子诊断专用MQI模型将Sigma度量融入框架。结果识别5个高风险失效模式并成功降至可接受水平(RPN<40),建立包含14项分析前、25项分析中和3项分析后QI的MQI,35项可评估QI中1项高风险和3项中风险均通过纠正措施处理。
要点
- FMEA整合QI可提高HPV基因分型检测风险评估的客观性。
- 5个高风险失效模式经优化后RPN降低20-80%。
- 建立的MQI含14项分析前、25项分析中、3项分析后QI。
核心结论
- 整合FMEA与QI的模型可用于HPV基因分型检测全过程风险评估,较传统方法提高客观性并支持多维分析。
研究设计与样本
- 多学科团队设计并实施覆盖分析前、分析中和分析后阶段的详细FMEA。
- 通过分子诊断专用MQI模型将Sigma度量整合入FMEA框架。
- 风险量化采用严重度、发生度(来自1年QI数据)和检测度评分(1-5分),计算RPN以排序失效模式。
- 对高风险项(RPN≥40)实施强制干预。
主要发现
- 识别5个高风险失效模式(如样本错误识别、数据分析错误),经流程优化和标准化后降至可接受水平(RPN<40),RPN降低20-80%。
- 建立分子诊断专用MQI,包含14项分析前、25项分析中和3项分析后QI。
- 对35项可评估QI进行基于QI的风险评估,发现1项高风险QI(信息系统故障导致结果错误)和3项中风险QI,均通过纠正措施处理。
关键数值与推荐
- 高风险失效模式定义为RPN≥40,需强制干预。
- 严重度、发生度和检测度均采用1-5分评分。
- 35项可评估QI中1项高风险、3项中风险。
临床怎么用
- 可将FMEA与QI整合模型用于HPV基因分型检测的全过程风险识别与优先干预。
- 利用1年QI数据估算发生度,提高风险评估的客观性。
- 对RPN≥40的高风险失效模式实施强制干预并验证降至RPN<40。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To develop a proactive risk assessment model for human papillomavirus (HPV) genotyping testing by integrating Failure Mode and Effects Analysis (FMEA) with quality indicators (QIs), ensuring compliance with ISO 15189:2022 and improving diagnostic accuracy. METHODS: A multidisciplinary team designed and performed detailed FMEA across pre-analytical, analytical, and post-analytical phases of HPV genotyping testing. To improve objectivity, we integrated Sigma metrics into the FMEA framework through a molecular diagnostics-specific model of QIs (MQI). The FMEA model systematically identified testing phases, potential failure modes, their effects, root causes, and existing controls. Risk was quantified using Severity, Occurrence (from 1-year QI data), and Detection scores (1-5 scale). Risk Priority Numbers (RPNs) were calculated (Severity × Occurrence × Detection) to prioritize failure modes, with mandatory interventions implemented for high-risk items (RPN≥40). RESULTS: Five high-risk failure modes (e.g., sample misidentification, data analysis errors) were identified and successfully mitigated to acceptable levels (RPN<40) through process optimization and standardization, achieving RPN reductions of 20-80 %. We established a molecular diagnostics-specific MQI, comprising 14 pre-analytical, 25 analytical, and three post-analytical phase QIs. QI-based risk assessment of 35 evaluable QIs for HPV genotyping testing revealed one high-risk QI ("Incorrect results due to information system failures") and three medium-risk QIs, all of which were addressed through corrective actions. CONCLUSIONS: This study developed an integrated FMEA-QI model for HPV genotyping testing, establishing both a traditional FMEA framework and a molecular diagnostics-specific MQI. The combined approach improves risk assessment objectivity and enables multidimensional analysis compared to conventional methods.
引用
- Li T, He Y, Chen Y, et al. Failure Mode and Effects Analysis (FMEA) integrating quality indicators for risk assessment of the total testing process in human papillomavirus genotyping testing: a proactive risk analysis model for molecular diagnostics. Clin Chem Lab Med. 2025. PMID: 40879430. doi:10.1515/cclm-2025-0598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。